Actelion's silver lining: macitentan dropped in IPF but safety data boost PAH hopes
30 August 2011
Eleanor Malone
Please Login to read the full article.
30 August 2011
Eleanor Malone
eleanor.malone@informa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- Boehringer Ingelheim's IPF drug impresses despite non-significant data
- InterMune prices Esbriet in Germany and Norway and raises $231m in equity and loans
- Disheartened investors put UTHR shares to the rack on FREEDOM-C2 failure
- BMS accesses fibrosis programme in $325 million deal for Amira
FEATURES
Other Informa Features
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
